Megan Test
Preview Text
All About Apoquel
{{custommediabasic::headline_subhead_alternate_style}}
{{custommediabasic::headline_all_caps}}
{{custommediabasic::headline_less_padding_bottom}}
#FF641D
#0196AF
{{custommediabasic::custom_background}}
30px 0 30px 0
{{custommediabasic::logo_url}}
/uploads/elanco-5068c2360f353356d58981f9014541fb.jpeg
Elanco
150
{{custommediabasic::logo_at_bottom}}
{{custommediabasic::header_image_url}}
/uploads/ce_1200_v_2-ff6747ada843cae3ba68075164384e07.jpg
{{custommediabasic::header_image_alt_text}}
All About Apoquel
{{custommediabasic::headline_smaller}}
What's a JAK Inhibitor?
{{custommediabasic::subhead_url}}
{{custommediabasic::headline_subhead_above_header_image}}
true
Just 5 years ago, a completely new class of drug, the Janus kinase inhibitor, was introduced to treat allergic dermatitis in dogs. Since that time, Apoquel (the first and only veterinary JAK inhibitor) has been prescribed to treat allergic pruritis and inflammation in over 6 million dogs, giving pet owner an attractive and effective alternative to corticosteriods. However, with widespread use of a new drug, and especially a totally new class of drug, there is no historical frame of reference around experiences with short-or-long term use. This sometimes leads to misunderstandings or bias based on only a few personal experiences.
We've brought together a roundtable of dermatologists, general practitioners, and oncologists to share their experiences and dispel the myths surrounding Apoquel.
{pb10}{subhead primary}Learn how 5 years of pharmacovigilance data have demonstrated:{/subhead}{/pb10}
- Apoquel is performing as expected
- In-depth pharmacovigilance data analysis does not show any unexpected results
- No causal relationship between administration of JAK inhibitors and development of neoplastic conditions
- Use of Apoquel has not shown increased risk for UTI
- Use of Apoquel with common parasiticides, antibiotics, and vaccines is considered safe
- While classified as an immunosuppressant, Apoquel appears to act more as a targeted immunomodulator.
#888888
{{custommediabasic::cta_big}}
{{custommediabasic::cta_center}}
{{custommediabasic::cta_callout}}
{{custommediabasic::cta_callout_secondary}}
https://www.cliniciansbrief.com/article/clinicians-forum-expert-views-roundtable-apoquel
Read the Discussion
Get Details
true
{{custommediabasic::footnote}}
{{custommediabasic::footnote_larger}}
{{custommediabasic::pre_footer_center}}
{{custommediabasic::pre_footer_larger}}
{{custommediabasic::pre_footer_copy}}
All About Apoquel
|
|
|
All About Apoquel
|
|
What's a JAK Inhibitor?
|
|
Just 5 years ago, a completely new class of drug, the Janus kinase inhibitor, was introduced to treat allergic dermatitis in dogs. Since that time, Apoquel (the first and only veterinary JAK inhibitor) has been prescribed to treat allergic pruritis and inflammation in over 6 million dogs, giving pet owner an attractive and effective alternative to corticosteriods. However, with widespread use of a new drug, and especially a totally new class of drug, there is no historical frame of reference around experiences with short-or-long term use. This sometimes leads to misunderstandings or bias based on only a few personal experiences. We've brought together a roundtable of dermatologists, general practitioners, and oncologists to share their experiences and dispel the myths surrounding Apoquel. {pb10}{subhead primary}Learn how 5 years of pharmacovigilance data have demonstrated:{/subhead}{/pb10} - Apoquel is performing as expected
- In-depth pharmacovigilance data analysis does not show any unexpected results
- No causal relationship between administration of JAK inhibitors and development of neoplastic conditions
- Use of Apoquel has not shown increased risk for UTI
- Use of Apoquel with common parasiticides, antibiotics, and vaccines is considered safe
- While classified as an immunosuppressant, Apoquel appears to act more as a targeted immunomodulator.
|
|
Read the Discussion
|
|
Read the Discussion
|
|
|
|
|
|
</head>
<body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#e8e8e8" bgcolor="#e8e8e8">
All About Apoquel
|
|
|
|
|
All About Apoquel
|
|
What's a JAK Inhibitor?
|
|
Just 5 years ago, a completely new class of drug, the Janus kinase inhibitor, was introduced to treat allergic dermatitis in dogs. Since that time, Apoquel (the first and only veterinary JAK inhibitor) has been prescribed to treat allergic pruritis and inflammation in over 6 million dogs, giving pet owner an attractive and effective alternative to corticosteriods. However, with widespread use of a new drug, and especially a totally new class of drug, there is no historical frame of reference around experiences with short-or-long term use. This sometimes leads to misunderstandings or bias based on only a few personal experiences. We've brought together a roundtable of dermatologists, general practitioners, and oncologists to share their experiences and dispel the myths surrounding Apoquel. {pb10}{subhead primary}Learn how 5 years of pharmacovigilance data have demonstrated:{/subhead}{/pb10} - Apoquel is performing as expected
- In-depth pharmacovigilance data analysis does not show any unexpected results
- No causal relationship between administration of JAK inhibitors and development of neoplastic conditions
- Use of Apoquel has not shown increased risk for UTI
- Use of Apoquel with common parasiticides, antibiotics, and vaccines is considered safe
- While classified as an immunosuppressant, Apoquel appears to act more as a targeted immunomodulator.
|
|
Read the Discussion
|
|
Read the Discussion
|
|
|
|
|
|
